NTLA Q3 EPS Estimate Decreased by Brookline Capital Markets

Posted by on May 13th, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) – Stock analysts at Brookline Capital Markets cut their Q3 2026 earnings per share (EPS) estimates for Intellia Therapeutics in a research report issued to clients and investors on Monday, May 11th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($0.74) for the quarter, down from their previous forecast of ($0.73). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.50) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics’ Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($2.76) EPS.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 55.63% and a negative net margin of 597.04%.The firm had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million.

Several other analysts have also commented on the company. Canaccord Genuity Group dropped their target price on Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday. reaffirmed a “buy” rating on shares of Intellia Therapeutics in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Tuesday, April 21st. Royal Bank Of Canada raised their target price on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a report on Tuesday, March 3rd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Intellia Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics presently has an average rating of “Hold” and an average price target of $20.14.

Check Out Our Latest Stock Report on Intellia Therapeutics

Intellia Therapeutics Stock Down 3.0%

Intellia Therapeutics stock opened at $13.99 on Wednesday. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -3.95 and a beta of 1.93. Intellia Therapeutics has a 52 week low of $6.83 and a 52 week high of $28.25. The business’s 50-day moving average price is $13.67 and its 200 day moving average price is $12.15.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NTLA. Comerica Bank lifted its position in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares in the last quarter. Headlands Technologies LLC purchased a new position in Intellia Therapeutics during the second quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new position in Intellia Therapeutics during the third quarter worth approximately $30,000. Advisory Services Network LLC purchased a new position in Intellia Therapeutics during the third quarter worth approximately $33,000. Finally, Spire Wealth Management purchased a new position in Intellia Therapeutics during the fourth quarter worth approximately $37,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

Featured Stories

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.